aromasil has been researched along with Ascites in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chekhun, VF; Grabovoy, AN; Lukyanova, NY; Svintsitsky, VS; Tarasova, TO; Tkalia, IG; Todor, IN; Vorobyova, LI | 1 |
| Grabovoy, AN; Svintsitsky, VS; Tarasova, TO; Tkalia, IG; Vorobyova, LI | 1 |
2 other study(ies) available for aromasil and Ascites
| Article | Year |
|---|---|
Increase of antitumor activity of cisplatin using agonist of gonadotropin-realising hormone and inhibitor of aromatase on the model of ascites ovarian tumor.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Androstadienes; Animals; Antineoplastic Agents; Apoptosis; Aromatase Inhibitors; Ascites; Cell Proliferation; Cisplatin; Disease Models, Animal; Drug Synergism; Female; Gonadotropin-Releasing Hormone; Immunoenzyme Techniques; Ovarian Neoplasms; Rats; Rats, Wistar; Triptorelin Pamoate; Tumor Cells, Cultured | 2014 |
The antitumor efficacy of cisplatin in combination with triptorelin and exemestane therapy for an ovarian cancer ascites model in Wistar rats.
Topics: Androstadienes; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ascites; Cisplatin; Female; Ovarian Neoplasms; Ovary; Rats; Rats, Wistar; Triptorelin Pamoate; Vascular Endothelial Growth Factor A | 2015 |